Trade IDEXX Laboratories, Inc. - IDXX CFD

Add to favourite

477.61

0.01%

0.45

Low: 475.1

High: 482.37

Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.45

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

IDEXX Laboratories Inc ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats

Prev. Close*	477.54
Open*	475.14
1-Year Change*	-1.3%
Day's Range*	475.1 - 482.37
52 wk Range	372.50-568.30
Average Volume (10 days)	539.69K
Average Volume (3 months)	10.75M
Market Cap	43.63B
P/E Ratio	53.60
Shares Outstanding	83.05M
Revenue	3.59B
EPS	9.80
Dividend (Yield %)	N/A
Beta	1.26
Next Earnings Date	Feb 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	477.61	-1.37	-0.29%	478.98	482.71	473.12
Apr 17, 2024	477.54	-6.64	-1.37%	484.18	489.72	477.45
Apr 16, 2024	489.27	-0.84	-0.17%	490.11	495.75	487.95
Apr 15, 2024	490.99	-12.89	-2.56%	503.88	503.88	489.65
Apr 12, 2024	497.43	0.64	0.13%	496.79	501.65	491.71
Apr 11, 2024	502.53	0.55	0.11%	501.98	508.47	500.15
Apr 10, 2024	503.60	-3.73	-0.74%	507.33	509.34	499.84
Apr 9, 2024	519.10	6.58	1.28%	512.52	522.21	507.89
Apr 8, 2024	514.30	-4.19	-0.81%	518.49	518.90	512.62
Apr 5, 2024	519.18	3.74	0.73%	515.44	523.75	515.44
Apr 4, 2024	517.98	-10.97	-2.07%	528.95	532.42	515.94
Apr 3, 2024	523.88	5.43	1.05%	518.45	530.42	518.45
Apr 2, 2024	521.46	-0.73	-0.14%	522.19	526.21	515.82
Apr 1, 2024	531.78	-1.69	-0.32%	533.47	539.66	526.69
Mar 28, 2024	538.01	0.36	0.07%	537.65	543.23	536.32
Mar 27, 2024	539.26	9.27	1.75%	529.99	540.63	529.99
Mar 26, 2024	530.40	3.65	0.69%	526.75	533.80	525.11
Mar 25, 2024	529.31	3.50	0.67%	525.81	529.84	523.27
Mar 22, 2024	530.28	-0.51	-0.10%	530.79	533.98	526.22
Mar 21, 2024	531.30	0.17	0.03%	531.13	541.13	529.32

IDEXX Laboratories, Inc. Events

Time (UTC)	Country	Event
Wednesday, May 1, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 IDEXX Laboratories Inc Earnings Call Q1 2024 IDEXX Laboratories Inc Earnings Call Forecast - Previous -
Time (UTC) 12:30	Country US	Event Q1 2024 IDEXX Laboratories Inc Earnings Release Q1 2024 IDEXX Laboratories Inc Earnings Release Forecast - Previous -
Monday, May 6, 2024
Time (UTC) 20:30	Country US	Event IDEXX Laboratories Inc Annual Shareholders Meeting IDEXX Laboratories Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, May 16, 2024
Time (UTC) 14:00	Country US	Event IDEXX Laboratories Inc Annual Shareholders Meeting IDEXX Laboratories Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, July 30, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 IDEXX Laboratories Inc Earnings Release Q2 2024 IDEXX Laboratories Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	3367.32	3215.36	2706.66	2406.91	2213.24
Revenue	3367.32	3215.36	2706.66	2406.91	2213.24
Cost of Revenue, Total	1362.99	1325.93	1135.61	1041.36	971.7
Gross Profit	2004.34	1889.43	1571.04	1365.55	1241.54
Total Operating Expense	2468.56	2283.33	2012.13	1854.06	1721.91
Selling/General/Admin. Expenses, Total	847.353	794.295	734.667	678.41	626.644
Research & Development	254.82	161.009	141.249	133.193	117.863
Interest Expense (Income) - Net Operating	3.4	2.1	0.6	1.1	3.1
Operating Income	898.765	932.028	694.524	552.846	491.335
Interest Income (Expense), Net Non-Operating	-38.793	-29.374	-32.539	-30.628	-33.593
Net Income Before Taxes	859.972	902.654	661.985	522.218	457.742
Net Income After Taxes	679.089	744.844	582.131	427.792	379.147
Minority Interest	0	0.001	-0.355	-0.072	-0.016
Net Income Before Extra. Items	679.089	744.845	581.776	427.72	379.131
Net Income	679.089	744.845	581.776	427.72	377.031
Income Available to Common Excl. Extra. Items	679.089	744.845	581.776	427.72	379.131
Income Available to Common Incl. Extra. Items	679.089	744.845	581.776	427.72	377.031
Diluted Net Income	679.089	744.845	581.776	427.72	377.031
Diluted Weighted Average Shares	84.6	86.572	86.722	87.542	88.47
Diluted EPS Excluding Extraordinary Items	8.02706	8.60376	6.70852	4.88588	4.28542
Diluted Normalized EPS	8.02706	8.65283	6.73388	4.88588	4.30976
Unusual Expense (Income)					2.6
Total Extraordinary Items					-2.1

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	943.63	900.195	828.568	841.661	860.546
Revenue	943.63	900.195	828.568	841.661	860.546
Cost of Revenue, Total	370.78	357.224	343.641	335.035	346.514
Gross Profit	572.85	542.971	484.927	506.626	514.032
Total Operating Expense	647.486	619.796	602.041	596.833	681.48
Selling/General/Admin. Expenses, Total	230.201	217.905	214.982	213.785	211.745
Research & Development	46.505	44.667	43.418	48.013	123.221
Operating Income	296.144	280.399	226.527	244.828	179.066
Interest Income (Expense), Net Non-Operating	-10.215	-12.711	-13.312	-10.645	-7.983
Net Income Before Taxes	285.929	267.688	213.215	234.183	171.083
Net Income After Taxes	224.236	214.054	172.207	180.938	131.979
Minority Interest			0	0	0
Net Income Before Extra. Items	224.236	214.054	172.207	180.938	131.979
Net Income	224.236	214.054	172.207	180.938	131.979
Income Available to Common Excl. Extra. Items	224.236	214.054	172.207	180.938	131.979
Income Available to Common Incl. Extra. Items	224.236	214.054	172.207	180.938	131.979
Diluted Net Income	224.236	214.054	172.207	180.938	131.979
Diluted Weighted Average Shares	83.983	83.959	83.826	84.113	84.858
Diluted EPS Excluding Extraordinary Items	2.67002	2.54951	2.05434	2.15113	1.55529
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	2.67002	2.54951	2.05434	2.15113	1.55529

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	1101.48	955.655	1062.74	679.639	654.172
Cash and Short Term Investments	112.546	144.454	383.928	90.326	123.794
Cash & Equivalents	112.546	144.454	383.928	90.326	123.794
Short Term Investments					0
Total Receivables, Net	490.903	425.584	374.742	307.487	272.623
Accounts Receivable - Trade, Net	442.473	406.12	355.266	286.971	258.525
Total Inventory	367.823	269.03	209.873	195.019	173.303
Prepaid Expenses	41.742	41.997	34.556	31.992	30.314
Other Current Assets, Total	88.463	74.59	59.639	54.815	54.138
Total Assets	2746.76	2437.2	2294.56	1832.47	1537.35
Property/Plant/Equipment, Total - Net	768.092	692.768	646.338	614.452	437.27
Property/Plant/Equipment, Total - Gross	1474.01	1341.16	1233.25	1133.48	906.003
Accumulated Depreciation, Total	-705.914	-648.391	-586.914	-519.03	-468.733
Goodwill, Net	361.795	359.345	243.347	239.724	214.489
Intangibles, Net	97.672	99.035	52.543	58.468	41.825
Long Term Investments	55.5	18.598	12.065	13.657	10.894
Other Long Term Assets, Total	212.541	187.836	179.52	145.349	147.43
Total Current Liabilities	1235.8	763.579	582.761	725.337	770.444
Accounts Payable	110.221	116.14	74.558	72.172	69.534
Accrued Expenses	385.115	416.304	372.972	288.944	233.471
Notes Payable/Short Term Debt	579	73.5	0	288.765	398.937
Other Current Liabilities, Total	86.485	82.639	85.243	75.456	68.502
Total Liabilities	2138.03	1747.21	1662.47	1655	1546.86
Total Long Term Debt	694.387	775.205	858.492	599.488	499.571
Long Term Debt	694.387	775.205	858.492	599.488	499.571
Deferred Income Tax	8.15	8.935	11.707	33.024	29.267
Minority Interest		0	0.707	0.352	0.28
Other Liabilities, Total	199.688	199.492	208.806	296.801	247.3
Total Equity	608.737	689.992	632.088	177.473	-9.513
Common Stock	15.901	16.407	15.149	15.033	15.033
Additional Paid-In Capital	1463.21	1377.32	1294.85	1213.52	1138.22
Retained Earnings (Accumulated Deficit)	3599.53	2920.44	2175.59	1595.65	1167.93
Treasury Stock - Common	-4392.11	-3570.69	-2799.89	-2600.54	-2288.9
Unrealized Gain (Loss)	-0.172	-0.126	-0.272	0.11	-0.157
Other Equity, Total	-77.624	-53.358	-53.343	-46.292	-41.634
Total Liabilities & Shareholders’ Equity	2746.76	2437.2	2294.56	1832.47	1537.35
Total Common Shares Outstanding	82.894	84.562	85.449	85.471	86.099
Note Receivable - Long Term	149.688	123.966	98.01	81.186	31.269
Current Port. of LT Debt/Capital Leases	74.982	74.996	49.988

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	1384.23	1179.03	1149.45	1101.48	1058.86
Cash and Short Term Investments	331.696	132.838	111.367	112.546	99.176
Cash & Equivalents	331.696	132.838	111.367	112.546	99.176
Total Receivables, Net	521.865	532.287	519.861	490.903	452.897
Accounts Receivable - Trade, Net	503.653	511.982	492.669	442.473	430.327
Total Inventory	393.974	395.141	391.011	367.823	354.975
Prepaid Expenses	49.875	38.918	40.084	41.742	39.696
Other Current Assets, Total	86.82	79.841	87.123	88.463	112.115
Total Assets	3086.4	2870.81	2808.4	2746.76	2640.07
Property/Plant/Equipment, Total - Net	804.883	797.418	780.499	768.092	722.508
Goodwill, Net	361.766	364.206	362.942	361.795	355.292
Intangibles, Net	87.129	90.932	94.361	97.672	99.968
Long Term Investments	54.333	55.391	54.271	55.5	51.76
Note Receivable - Long Term	159.196	159.369	153.757	149.688	142.031
Other Long Term Assets, Total	234.867	224.465	213.122	212.541	209.649
Total Current Liabilities	970.193	883.859	1065.63	1235.8	1189.94
Accounts Payable	112.609	107.664	117.709	110.221	110.144
Accrued Expenses	370.053	343.016	330.763	385.115	371.286
Notes Payable/Short Term Debt	250	264	431.5	579	633
Current Port. of LT Debt/Capital Leases	149.99	74.991	74.986	74.982	0
Other Current Liabilities, Total	87.541	94.188	110.671	86.485	75.515
Total Liabilities	1789	1776.94	1967.3	2138.03	2164.07
Total Long Term Debt	618.813	696.844	696.362	694.387	760.814
Long Term Debt	618.813	696.844	696.362	694.387	760.814
Deferred Income Tax	10.594	5.568	5.826	8.15	14.486
Minority Interest
Other Liabilities, Total	189.397	190.674	199.48	199.688	198.823
Total Equity	1297.41	1093.86	841.101	608.737	475.999
Common Stock	16.268	16.253	15.896	15.901	15.885
Additional Paid-In Capital	1543.02	1515.2	1489.9	1463.21	1437.53
Retained Earnings (Accumulated Deficit)	4250.05	4037.82	3813.58	3599.53	3427.32
Treasury Stock - Common	-4437.04	-4401.74	-4401.67	-4392.11	-4323.84
Unrealized Gain (Loss)	-0.166	-0.165	-0.166	-0.172	-0.178
Other Equity, Total	-74.725	-73.5	-76.449	-77.624	-80.716
Total Liabilities & Shareholders’ Equity	3086.4	2870.81	2808.4	2746.76	2640.07
Total Common Shares Outstanding	83.068	83.06	83.004	82.894	82.995

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	679.089	744.844	582.131	427.792	377.047
Cash From Operating Activities	542.984	755.546	648.063	459.158	400.084
Cash From Operating Activities	111.9	104.596	95.998	88.011	83.178
Deferred Taxes	-35.065	-3.377	-38.082	6.162	1.209
Non-Cash Items	60.59	47.006	39.777	42.162	30.29
Cash Taxes Paid	239.8	161.7	110.7	88	69.7
Cash Interest Paid	39.5	30.5	32.4	29.7	34.7
Changes in Working Capital	-273.53	-137.523	-31.761	-104.969	-91.64
Cash From Investing Activities	-195.35	-292.967	-109.376	-205.528	138.602
Capital Expenditures	-158.838	-119.549	-107.876	-155.224	-122.936
Other Investing Cash Flow Items, Total	-36.512	-173.418	-1.5	-50.304	261.538
Cash From Financing Activities	-370.936	-697.414	-248.416	-286.409	-597.799
Financing Cash Flow Items	-17.472	-20.702	-27.304	-10.582	-10.641
Issuance (Retirement) of Stock, Net	-783.964	-700.212	-131.487	-265.552	-331.118
Issuance (Retirement) of Debt, Net	430.5	23.5	-89.625	-10.275	-256.04
Foreign Exchange Effects	-8.606	-4.639	3.331	-0.689	-4.768
Net Change in Cash	-31.908	-239.474	293.602	-33.468	-63.881

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	214.054	679.089	506.882	325.944	193.965
Cash From Operating Activities	183.912	542.984	369.556	180.556	114.706
Cash From Operating Activities	28.331	111.9	83.18	54.633	26.511
Deferred Taxes	-3.757	-35.065	-36.89	-23.517	-5.028
Non-Cash Items	15.893	60.59	45.981	30.447	13.5
Cash Taxes Paid	7.2	239.8	179.72	128.325	11.4
Changes in Working Capital	-70.609	-273.53	-229.597	-206.951	-114.242
Cash From Investing Activities	-39.511	-195.35	-146.121	-96.924	-41.838
Capital Expenditures	-39.511	-158.838	-109.609	-71.924	-41.838
Other Investing Cash Flow Items, Total		-36.512	-36.512	-25	0
Cash From Financing Activities	-146.081	-370.936	-254.216	-105.387	-13.48
Financing Cash Flow Items	-11.377	-17.472	-16.282	-13.206	-10.338
Issuance (Retirement) of Stock, Net	12.796	-783.964	-722.434	-554.681	-254.642
Issuance (Retirement) of Debt, Net	-147.5	430.5	484.5	462.5	251.5
Foreign Exchange Effects	0.501	-8.606	-14.497	-8.337	0.776
Net Change in Cash	-1.179	-31.908	-45.278	-30.092	60.164
Cash Interest Paid		39.5

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

IDEXX Labs Company profile

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. It also sells a line of portable electrolytes and blood gas analyzers used in the human diagnostics market. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment CAG develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services that are used to manage the health status of livestock and poultry.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, IDEXX Laboratories, Inc. revenues increased 19% to $3.22B. Net income increased 28% to $744.8M. Revenues reflect CAG segment increase of 21% to $5.42B, Water segment increase of 14% to $146.5M, United States segment increase of 18% to $2B, Canada segment increase of 30% to $139.7M, Germany segment increase of 23% to $146.8M. Net income benefited from CAG segment income increase of 43% to $824M.

Equity composition

Common Stock $.10 Par, 06/11, 120M auth., 98,835,000 issd., less 42,004,000 shs. in Treas. @ $1.16B. Insiders control approx.1.09%. IPO: 4/92, 1.5M shares @ $20.50 by Lehman Brothers. PO: 10/95, 4.6M shares @ $35 by Cowen & Company. 11/07, 6/95 & 10/93, 2-for-1 stock splits. 06/15, 2-for-1, Stock Split.

Industry:

Veterinary Medical Equipment & Supplies

One Idexx Drive
WESTBROOK
MAINE 04092-2041
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024